Target-mediated drug disposition model and its approximations for antibody-drug conjugates.
about
Challenges and advances in the assessment of the disposition of antibody-drug conjugatesA mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.Population Pharmacokinetics of Necitumumab in Cancer Patients.Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug ConjugatesApplication of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.In vitro-in vivo correlations: general concepts, methodologies and regulatory applications.Integration of bioanalytical measurements using PK-PD modeling and simulation: implications for antibody-drug conjugate development.Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling.Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study.Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody-drug conjugates in biological matrices.Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Comparative untargeted proteomic analysis of ADME proteins and tumor antigens for tumor cell lines.
P2860
Q28085074-8A0732BF-2A3B-42F2-B796-AF65F9DA54B3Q34099745-CA659E26-294E-492D-95CB-8ACB23D3B774Q34403364-D9AF979B-50CC-4406-A1CE-480C4FA62DD9Q37742626-696C62B1-8385-4D19-A71A-A8D02AD5A4A9Q38275051-8B31C34E-F99F-46AC-A43B-00CB913D40F6Q38350045-FEAFBBC4-9D79-4B17-BFDC-A805205EA199Q38452569-4F6F8BF8-A489-4629-8F8E-9753C0A6FDFFQ38453769-FB51D11E-13D5-4B4B-97C1-C28E807459DBQ38541574-F7D7AF61-9533-4000-B5D3-F4F926B784A8Q38557522-770B494C-090B-41B5-8750-597A9D602882Q38764062-1D10AEB4-9199-455B-9A3D-7421F6E05F54Q38962519-0B6B2EC5-5EFA-4CA3-B3A5-04D7FC689612Q39174329-6CC566F2-0361-421C-AEBC-8F125E228118Q39742601-6DFD6F23-445F-4DA6-B4D2-5756C03C0C97Q40677793-C766DF83-EDE2-4CEF-AA9A-D8E0D28D9B66Q41526288-9E9B098B-8019-4A3D-9BDE-FC9C31071712Q46155633-318D93FC-6AC1-4B7C-9ED2-BCEF6FCD12C9Q47973033-93B03A1C-F992-4BCD-B25F-05F3D42CB0B7Q48015255-65EC799E-B4CF-4171-958C-E92D5399DD57Q48273553-FA9E1424-DA5C-4F18-AA3D-158641FF9CA9Q49315568-6BD96206-D711-4847-983B-37B181EFFA0AQ54941547-B8CF45F1-1FC6-48E4-80ED-CBAAFD3A15F4
P2860
Target-mediated drug disposition model and its approximations for antibody-drug conjugates.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Target-mediated drug dispositi ...... for antibody-drug conjugates.
@en
Target-mediated drug dispositi ...... for antibody-drug conjugates.
@nl
type
label
Target-mediated drug dispositi ...... for antibody-drug conjugates.
@en
Target-mediated drug dispositi ...... for antibody-drug conjugates.
@nl
prefLabel
Target-mediated drug dispositi ...... for antibody-drug conjugates.
@en
Target-mediated drug dispositi ...... for antibody-drug conjugates.
@nl
P2860
P1476
Target-mediated drug dispositi ...... for antibody-drug conjugates.
@en
P2093
Ekaterina Gibiansky
Leonid Gibiansky
P2860
P2888
P356
10.1007/S10928-013-9344-Y
P577
2013-12-11T00:00:00Z